Inmune Bio, Inc.
INMB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INMB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INMB
Inmune Bio, Inc. is a clinical-stage biotechnology company developing a natural killer (NK) cell-priming platform, INKmune, for cancer, currently in Phase 1, with limited cash runway and a going concern risk.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials for Inmune Bio, Inc..
Inmune Bio, Inc. is a clinical-stage biotechnology company developing a natural killer (NK) cell-priming platform, INKmune, for cancer, currently in Phase 1, with limited cash runway and a going concern risk.
- Pipeline candidate INKmune is a natural killer (NK) cell-priming platform in Phase 1 for cancer [pipeline].
- Cash and equivalents were $18.4 million as of 2026-06-30 [sec].
- Net loss was $1.3 million for the period ended 2026-06-30 [sec].
- Shareholders' equity was $20.4 million as of 2026-06-30 [sec].
- The company has a going concern risk, with cash projected insufficient to sustain operations for one year after the latest financial statement date [sec_mda · as of 2026-08-06].
What works
- INKmune targets a large addressable market of $1.4 billion with a novel NK cell-priming mechanism [pipeline].
- The company uses CROs to manage spending, providing operational flexibility [sec_mda · as of 2026-05-07].
What to weigh
- Cash of $18.4 million as of 2026-06-30 is projected insufficient to sustain operations through one year, raising substantial doubt about going concern [sec_mda · as of 2026-08-06].
- The company has a history of net losses ($45.9 million in 2025, $42.1 million in 2024) and expects losses to increase [sec_mda · as of 2026-03-30].
- Product candidates are not expected to be commercially available for at least several years, if ever [sec_mda · as of 2026-08-06].
- Development costs are highly uncertain and cannot be reasonably estimated at this time [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cash is insufficient to sustain operations for one year.
“million at June 30, 2026, which the Company is projecting will be insufficient to sustain its operations through one year following the date that the financial statements are issued.”
SEC MD&A · August 6, 2026
INKmune is a Phase 1 NK cell-priming platform for cancer.
“Pipeline Candidate: inkmune Indication: Cancer Phase: Phase 1 Mechanism of Action: Natural killer (NK) cell-priming platform”
Net losses were $45.9 million in 2025 and $42.1 million in 2024.
“We reported a net loss of $45.9 million and $42.1 million for the years ended December 31, 2025 and 2024, respectively.”
SEC MD&A · March 30, 2026
Product candidates are not expected to be commercially available for several years.
“our product candidates to be commercially available for at least the next several years, if ever.”
SEC MD&A · August 6, 2026
Risks & what to watch (3)›
Key risks
- Going concern risk — Cash of $18.4M as of 2026-06-30 is projected insufficient to sustain operations for one year [sec_mda · as of 2026-08-06].
- Development cost uncertainty — Costs and timelines for completing development of product candidates cannot be reasonably estimated [sec_mda · as of 2026-08-06].
- Dependence on additional financing — If additional capital is not available, the company may need to delay, scale back, or discontinue development [sec_mda · as of 2026-08-06].
What to watch
- Ability to raise additional capital to extend cash runway beyond 2026-06-30 [sec_mda · as of 2026-08-06].
- Progress of INKmune Phase 1 clinical trial results [pipeline].
- Changes in net loss and cash burn rate in upcoming quarterly reports [sec_mda · as of 2026-03-30].
Sources: Pipeline · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Inmune Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Inmune Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
18.9 months
D/E 0.32 · 0% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
81
Total value held
$7.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,374,030 | $1.6M |
| blackrock, inc. | 1,194,112 | $1.3M |
| geode capital management, llc | 494,969 | $559K |
| eversource wealth advisors, llc | 4,295 | $427K |
| state street corp | 290,879 | $329K |
| aqr capital management llc | 270,317 | $305K |
| susquehanna international group, llp | 243,191 | $275K |
| goldman sachs group inc | 231,586 | $262K |
| raymond james financial inc | 203,245 | $230K |
| northern trust corp | 184,225 | $208K |
Showing top 10 of 81 institutional holders of Inmune Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 16.9%
- Days to cover
- 6.4
- Shares short
- 3,425,591
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INMB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Inmune Bio, Inc.?
Inmune Bio, Inc. is a clinical-stage biotechnology company developing a natural killer (NK) cell-priming platform, INKmune, for cancer, currently in Phase 1, with limited cash runway and a going concern risk.
What is Inmune Bio, Inc.'s lead drug candidate?
Inmune Bio, Inc.'s most advanced tracked candidate is cordstrom (Phase 3) for Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Who is the CEO of Inmune Bio, Inc.?
Mr. David J. Moss M.B.A. is the chief executive officer of Inmune Bio, Inc. (INMB).
Where is Inmune Bio, Inc. headquartered?
Inmune Bio, Inc. (INMB) is headquartered in Boca Raton, FL, United States.
What therapeutic areas does Inmune Bio, Inc. focus on?
Inmune Bio, Inc. develops therapies across Oncology, Gene Therapy, Neurology, Infectious Disease, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.